亚洲av无码电影在线播放,人妻中文字幕无码专区

JNJ-678

NMR下載 COA and HPLC MSDS下載
names：
JNJ-678
CAS號：
1383450-81-4
MDL Number： MFCD30489307
MF(分子式)： C21H20ClF3N4O3S MW(分子量)： 500.92
EINECS:No data available Reaxys Number:No data available
Pubchem ID:118892432 Brand:BIOFOUNT

JNJ-678 (1383450-81-4,JNJ-53718678) 是新型融合蛋白 (fusion protein) 抑制劑，有潛力用于呼吸道合胞病毒 (RSV)的研究。

貨品編碼	規(guī)格	純度	價格 (￥)	現(xiàn)價(￥)	特價(￥)	庫存描述	數(shù)量	總計 (￥)
YZM000872-10mg	10mg	98%	￥ 7594.00	￥ 7594.00		2-3天	- +	￥ 0.00
YZM000872-5mg	5mg	98%	￥ 4488.00	￥ 4488.00		2-3天	- +	￥ 0.00

大包裝詢價提供各種包裝，敬請垂詢
收藏商品商品點評加入購物車立即購買

快速詢價

收起

你想詢價的產品

*產品名稱：

CAS號：

產品編號：

需求描述：

請準確填寫您的聯(lián)系方式，以便為您提供最好的服務。

*公司名稱：

*電子郵箱：

聯(lián)系人：

*電話：

*驗證碼：

詢價

中文別名	JNJ-678(1383450-81-4);JNJ-53718678;Rilematovir
英文別名	JNJ-678(1383450-81-4)
CAS號	1383450-81-4
Inchi	InChI=1S/C21H20ClF3N4O3S/c1-33(31,32)8-2-7-27-16(10-14-9-15(22)3-4-17(14)27)12-28-19-11-26-6-5-18(19)29(20(28)30)13-21(23,24)25/h3-6,9-11H,2,7-8,12-13H2,1H3
InchiKey	GTQTUABHRCWVLL-UHFFFAOYSA-N
分子式 Formula	C21H20ClF3N4O3S
分子量 Molecular Weight	500.92
溶解度Solubility	生物體外In Vitro:DMSO溶解度65 mg/mL(129.76 mM;Need ultrasonic)H2O< 0.1 mg/mL(insoluble)
性狀	白色至灰白色固體粉末
儲藏條件 Storage conditions	-20°C 3 years年 4°C 2 years年 / 溶液中:-80°C 6 months月 -20°C 1 month月

JNJ-678 (1383450-81-4,JNJ-53718678)實驗注意事項：
1.實驗前需戴好防護眼鏡，穿戴防護服和口罩，佩戴手套，避免與皮膚接觸。
2.實驗過程中如遇到有毒或者刺激性物質及有害物質產生，必要時實驗操作需要手套箱內完成以免對實驗人員造成傷害
3.實驗后產生的廢棄物需分類存儲，并交于專業(yè)生物廢氣物處理公司處理，以免造成環(huán)境污染

JNJ-678 (1383450-81-4,JNJ-53718678) Experimental considerations:
1. Wear protective glasses, protective clothing and masks, gloves, and avoid contact with the skin during the experiment.
2. The waste generated after the experiment needs to be stored separately, and handed over to a professional biological waste gas treatment company to avoid environmental pollution.

Tag:JNJ-678 (1383450-81-4,JNJ-53718678),NJ-678試劑,NJ-678抑制劑,NJ-678的生產,NJ-678的純度,NJ-678的作用,NJ-678的含量,NJ-678的使用,NJ-678的合成,NJ-678的MSDS,NJ-678的價格,NJ-678的外觀,NJ-678的溶解度

產品說明	JNJ-678 (1383450-81-4,JNJ-53718678) 是新型融合蛋白的抑制劑，臨床試驗中用于治療呼吸道合胞病毒 (RSV)
Introduction	JNJ-678 (1383450-81-4,JNJ-53718678) is a novelfusion proteininhibitor in clinical trials for the treatment of respiratory syncytial virus (RSV).
Application1
Application2
Application3

警示圖
危險性	warning
危險性警示	Not available
安全聲明	H303吞入可能有害+H313皮膚接觸可能有害+H2413吸入可能對身體有害
安全防護	P264處理后徹底清洗+P280戴防護手套/穿防護服/戴防護眼罩/戴防護面具+P305如果進入眼睛+P351用水小心沖洗幾分鐘+P338取出隱形眼鏡（如果有）并且易于操作,繼續(xù)沖洗+P337如果眼睛刺激持續(xù)+P2393獲得醫(yī)療建議/護理
備注	實驗過程中防止吸入、食入，做好安全防護

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article)

Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor PMID 31832988;

A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor PMID 28761099; Nature communications 2017 08; 8(1):167

Advances in respiratory virus therapeutics - A meeting report from the 6th isirv Antiviral Group conference PMID 30974127; Antiviral research 2019 07; 167(?):45-67 (Review Article)

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor
Abstract:Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today. Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure-activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors. Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.Respiratory syncytial virus causes lung infections in children, immunocompromised adults, and in the elderly. Here the authors show that a chemical inhibitor to a viral fusion protein is effective in reducing viral titre and ameliorating infection in rodents and neonatal lambs.

對不起，暫無產品評價！

MSDS

SDS 1.0 中文

展開

SDS 1.0 英文

展開